Psychopharmacology · 2025
Haloperidol - norepinephrine synergy in stimulation of vacuous chewing movements in rats: Enhancement by nicotine.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ionov Ilya D, Krasilova Maria D, Gorev Niсholas P, Tulchinskiy Victor I, Gabov Sergey A, Lyubimova Margarita O, Maltseva Lyudmila I, Komikarov Piotr N
Аннотация
RATIONALE: Tardive dyskinesia (TD), a late onset involuntary repetitive movements, is a complication of antipsychotic therapy. The mechanism of TD development is currently obscure. In TD patients, an increased brain level of norepinephrine was found; the pathogenic significance of this abnormality is unclear. The chronic administration of haloperidol in rodents induces a specific stereotyped behavior called vacuous chewing movements (VCM) that resembles TD and is used as a routine TD model. Meanwhile, this model does not mirror such a feature of TD as an exacerbation by tobacco smoking.
OBJECTIVES: We examined the hypotheses that (i) sustained brain norepinephrine hyperactivity influences the development of haloperidol-induced VCM; and (ii) VCM induced by haloperidol-norepinephrine combination, are enhanced by nicotine.
METHODS: Male Sprague-Dawley rats were used. VCM were exerted by 25-day administration of haloperidol; to simulate an increase in brain norepinephrine levels this agent was injected intracerebroventricularly for 14 consecutive days. Nicotine was given daily concurrently with norepinephrine.
RESULTS: Separated administration of haloperidol and norepinephrine at low doses resulted in no effect; however, their co-administration induced a clear stimulation of VCM. The chronic nicotine treatment did not affect the haloperidol-induced VCM but strongly enhanced the effect induced by the haloperidol + norepinephrine combination.
CONCLUSIONS: It was found for the first time that haloperidol and norepinephrine synergistically stimulate VCM; this finding can advance our understanding of TD pathogenesis. In the light of these results, norepinephrine may be a promising therapeutic target in TD. Given the obtained results, the haloperidol + norepinephrine-induced VCM seem to be more reasonable model for TD than haloperidol-only one.
OBJECTIVES: We examined the hypotheses that (i) sustained brain norepinephrine hyperactivity influences the development of haloperidol-induced VCM; and (ii) VCM induced by haloperidol-norepinephrine combination, are enhanced by nicotine.
METHODS: Male Sprague-Dawley rats were used. VCM were exerted by 25-day administration of haloperidol; to simulate an increase in brain norepinephrine levels this agent was injected intracerebroventricularly for 14 consecutive days. Nicotine was given daily concurrently with norepinephrine.
RESULTS: Separated administration of haloperidol and norepinephrine at low doses resulted in no effect; however, their co-administration induced a clear stimulation of VCM. The chronic nicotine treatment did not affect the haloperidol-induced VCM but strongly enhanced the effect induced by the haloperidol + norepinephrine combination.
CONCLUSIONS: It was found for the first time that haloperidol and norepinephrine synergistically stimulate VCM; this finding can advance our understanding of TD pathogenesis. In the light of these results, norepinephrine may be a promising therapeutic target in TD. Given the obtained results, the haloperidol + norepinephrine-induced VCM seem to be more reasonable model for TD than haloperidol-only one.